{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:47:04Z","timestamp":1762195624232,"version":"build-2065373602"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW012466"],"award-info":[{"award-number":["D43TW012466"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sickle cell disease is the 12\n                      <jats:sup>th<\/jats:sup>\n                      cause of under-five mortality in Africa, with over 81,000 deaths attributed to sickle cell disease annually. Hydroxyurea is one of the few disease-modifying therapies available for the management of sickle cell disease. This study aimed to assess changes in haematological indices among children who had been initiated on hydroxyurea for at least one year in a non-trial setting at a regional referral hospital in Eastern Uganda.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cohort study, which included children who attended the sickle cell clinic from 21\/Aug\/2024 to 30\/Oct\/2024. Data were analyzed using Stata version 18.0. We conducted a paired sample t-test comparing the haematological indices of children with sickle cell disease at baseline and at least one year later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 324 children. Nearly half 155\/324 (47.8%) of the participants had good monthly adherence to hydroxyurea. The mean haemoglobin level at follow-up increased by 0.77g\/dl (p &lt;0.001) from 7.07g\/dl (SD 0.10) at baseline to 7.84g\/dl (SD 0.09). There was an increase in the mean corpuscular volume [0.97fl (p=0.645)] and mean corpuscular haemoglobin [0.58pg (p=0.120)]. The white blood cell count decreased by 6.17x10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u00b5l (p&lt;0.001) from 20.77x10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u00b5l (SD \u00b1 0.806) at baseline to 14.60x10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u00b5l (SD \u00b1 0.613) at follow-up. The differential white cell counts of neutrophils, lymphocytes, monocytes, and basophils also decreased.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hydroxyurea resulted in an increase in mean haemoglobin level and a decrease in absolute and differential white blood cell count. The benefit was more pronounced among children with good adherence to hydroxyurea. We add our voice to calls for continued advocacy for the availability of hydroxyurea for use by children with sickle cell disease in low-resource settings. We also recommend a routine complete blood count to monitor response to treatment and also guide patient management among children with sickle cell disease initiated on hydroxyurea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335617","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:26:37Z","timestamp":1762194397000},"page":"e0335617","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in haematological indices among children with sickle cell disease on hydroxyurea treatment for at least 1 year: A cohort study"],"prefix":"10.1371","volume":"20","author":[{"given":"Stephen","family":"Emuli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crispus","family":"Tegu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7481-3321","authenticated-orcid":true,"given":"Faith","family":"Oguttu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritah","family":"Nantale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ochieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Passi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Abeso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Wamulugwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton W.","family":"Musaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Namazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kiguli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Mukunya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"8","key":"pone.0335617.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"AM Thomson","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"2","key":"pone.0335617.ref002","doi-asserted-by":"crossref","first-page":"021103","DOI":"10.7189\/jogh.08.021103","article-title":"The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis","volume":"8","author":"E Wastnedge","year":"2018","journal-title":"J Glob Health"},{"issue":"4","key":"pone.0335617.ref003","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.seminhematol.2023.08.002","article-title":"Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa","volume":"60","author":"M Ally","year":"2023","journal-title":"Semin Hematol"},{"issue":"11","key":"pone.0335617.ref004","first-page":"1749","volume":"14","author":"PT McGann","year":"2015","journal-title":"Hydroxyurea therapy for sickle cell anemia"},{"issue":"18","key":"pone.0335617.ref005","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"RE Ware","year":"2011","journal-title":"Blood"},{"issue":"2","key":"pone.0335617.ref006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa","volume":"380","author":"L Tshilolo","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0335617.ref007","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia","volume":"130","author":"RO Opoka","year":"2017","journal-title":"Blood"},{"issue":"1","key":"pone.0335617.ref008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/pbc.25705","article-title":"Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial","volume":"63","author":"PT McGann","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"pone.0335617.ref009","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood.2023021575","article-title":"Hydroxyurea reduces infections in children with sickle cell anemia in Uganda","volume":"143","author":"R Namazzi","year":"2024","journal-title":"Blood"},{"issue":"3","key":"pone.0335617.ref010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0895-4356(00)00305-X","article-title":"Are randomized clinical trials good for us (in the short term)? Evidence for a \u201ctrial effect\u201d","volume":"54","author":"DA Braunholtz","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"pone.0335617.ref011","volume-title":"Essential Medicines and Health Supplies List for Uganda (EMHSLU)","author":"Ministry of health Uganda","year":"2016"},{"key":"pone.0335617.ref012","volume-title":"Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production","author":"G Dover","year":"1986"},{"issue":"7","key":"pone.0335617.ref013","first-page":"493","article-title":"Effect of hydroxyurea on clinical and haematological profile of children with sickle cell anaemia","volume":"7","author":"SK Barma","year":"2020","journal-title":"Res Rev"},{"issue":"2","key":"pone.0335617.ref014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.32677\/IJCH.2021.v08.i02.008","article-title":"Impact of hydroxyurea therapy on clinicohematological parameters in children with sickle cell anemia","volume":"8","author":"N Joshi","year":"2021","journal-title":"Indian J Child Health"},{"issue":"3","key":"pone.0335617.ref015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5539\/gjhs.v8n3p252","article-title":"Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia","volume":"8","author":"B Keikhaei","year":"2015","journal-title":"Glob J Health Sci"},{"issue":"2","key":"pone.0335617.ref016","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"L Luchtman-Jones","year":"2016","journal-title":"Am J Hematol"},{"key":"pone.0335617.ref017","doi-asserted-by":"crossref","first-page":"7753857","DOI":"10.1155\/2021\/7753857","article-title":"Mechanisms of Hydroxyurea-Induced Cellular Senescence: An Oxidative Stress Connection?","volume":"2021","author":"S Kapor","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"26","key":"pone.0335617.ref018","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"RE Ware","year":"2010","journal-title":"Blood"},{"issue":"3","key":"pone.0335617.ref019","first-page":"273","article-title":"Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia","volume":"89","author":"DT Covas","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"pone.0335617.ref020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"HM Lederman","year":"2014","journal-title":"Pediatrics"},{"issue":"7","key":"pone.0335617.ref021","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"JS Hankins","year":"2005","journal-title":"Blood"},{"issue":"2","key":"pone.0335617.ref022","article-title":"Hydroxyurea use among children with sickle cell disease at King Abdulaziz University Hospital in Jeddah City","volume":"13","author":"F Alzahrani","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"pone.0335617.ref023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5581\/1516-8484.20110029","article-title":"Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros","volume":"33","author":"FKS Santos","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"pone.0335617.ref024","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.V96.4.1582","article-title":"Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera","volume":"96","author":"A Tefferi","year":"2000","journal-title":"Blood"},{"key":"pone.0335617.ref025","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood-2019-125128","article-title":"Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study","volume":"134","author":"CC John","year":"2019","journal-title":"Blood"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:26:42Z","timestamp":1762194402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335617"}},"subtitle":[],"editor":[{"given":"Santosh L.","family":"Saraf","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335617","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}